Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA, Eggs and healthy food
FDA receives reports almost daily from different food companies regarding potential allergens or foodborne illnesses.
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The U.S. Food and Drug Administration (FDA) has announced a final rule updating the definition of the nutrient content claim “healthy.” To qualify ...
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
If your drug trials don't succeed, try again with another drug — and raise more money. That's $RAPT's plan as it targets food ...
Under the previous FDA rule, which is being updated for the first time in 30 years, foods like salmon couldn't be labeled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback